Format

Send to

Choose Destination
Vaccine. 2016 Aug 5;34(36):4313-20. doi: 10.1016/j.vaccine.2016.06.075. Epub 2016 Jul 12.

Modeling pneumococcal nasopharyngeal acquisition as a function of anticapsular serum antibody concentrations after pneumococcal conjugate vaccine administration.

Author information

1
The Faculty of Health Sciences, The Ben-Gurion University of the Negev, POB 653, Beer-Sheva 84105, Israel. Electronic address: rdagan@bgu.ac.il.
2
Pfizer Pharma GmbH, Linkstrasse 10, 10785 Berlin, Germany. Electronic address: Christine.Juergens@pfizer.com.
3
inVentiv Health Clinical, 504 Carnegie Center, Princeton, NJ 08540, USA. Electronic address: james.trammel@inventivhealth.com.
4
Pfizer Vaccines Research, Pfizer Inc., 401 N Middletown Road, Pearl River, NY 10965, USA. Electronic address: Scott.Patterson@Pfizer.com.
5
The Faculty of Health Sciences, The Ben-Gurion University of the Negev, POB 653, Beer-Sheva 84105, Israel; The Pediatric Infectious Disease Unit, Soroka University Medical Center, The Ben-Gurion University of the Negev, POB 151, Beer-Sheva 84101, Israel. Electronic address: dudi@bgu.ac.il.
6
The Faculty of Health Sciences, The Ben-Gurion University of the Negev, POB 653, Beer-Sheva 84105, Israel; The Pediatric Infectious Disease Unit, Soroka University Medical Center, The Ben-Gurion University of the Negev, POB 151, Beer-Sheva 84101, Israel. Electronic address: givon@bgu.ac.il.
7
The Faculty of Health Sciences, The Ben-Gurion University of the Negev, POB 653, Beer-Sheva 84105, Israel; The Pediatric Infectious Disease Unit, Soroka University Medical Center, The Ben-Gurion University of the Negev, POB 151, Beer-Sheva 84101, Israel. Electronic address: npurat@bgu.ac.il.
8
Pfizer Vaccines Research, Pfizer Inc., 401 N Middletown Road, Pearl River, NY 10965, USA. Electronic address: Bill.Gruber@Pfizer.com.
9
Pfizer Vaccines Research, Pfizer Inc., 401 N Middletown Road, Pearl River, NY 10965, USA. Electronic address: Dan.Scott@Pfizer.com.

Abstract

BACKGROUND:

A prior 7- and 13-valent pneumococcal conjugate vaccine (PCV7 and PCV13) study provided sufficient data (N=1754; Jewish, n=1154; Bedouin, n=595; other, n=5) to investigate the association between nasopharyngeal (NP) acquisition of common PCV7 serotypes and cross-reacting 6A (PCV7+6A) and IgG concentrations.

METHODS:

Using a logistic regression model, serotype specific association between postinfant series IgG concentration (age 7months) and new NP acquisition between ages 7 and 24months was assessed and adjusted for ethnicity. From a subset of subjects with new NP acquisition (n=9-152 across serotypes studied), new acquisition percentiles and associated IgG concentrations were calculated.

RESULTS:

For the serotypes studied, new NP acquisition rates decreased as IgG concentrations increased. Ethnicity did not influence these associations despite differences in carriage rates. From the subset with new acquisitions, 50% of the events occurred at IgG concentrations >0.61-5.58μg/mL; and 10% of the acquisitions occurred at IgG concentrations >2.48-17.69μg/mL.

CONCLUSION:

Remarkably high IgG concentrations are required to reduce NP acquisition. These IgG concentrations differ between serotypes. Ethnicity did not influence the association between high IgG concentrations and prevention of carriage despite differences in carriage rates. Since carriage determines transmission, these results may have important implications for herd protection.

TRIAL REGISTRATION:

ClinicalTrials.gov number, NCT00508742; http://clinicaltrials.gov/ct2/show/NCT00508742.

KEYWORDS:

Antibody concentrations; Indirect protection; Modeling; Nasopharyngeal colonization; Pneumococcal conjugate vaccine; Streptococcus pneumoniae

PMID:
27422342
DOI:
10.1016/j.vaccine.2016.06.075
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center